NCT01482676 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Bartel DP
MicroRNAs: target recognition and regulatory functions. Cell. 2009 Jan 23;136(2):215-33. doi: 10.1016/j.cell.2009.01.002. Review.
Cardozo LD, Van Kerrebroeck PE, Staskin DR
Considerations for the management of urgency symptoms in patients with overactive bladder syndrome. World J Urol. 2009 Dec;27(6):755-63. doi: 10.1007/s00345-009-0455-4. Review.
Donaldson MM, Thompson JR, Matthews RJ, Dallosso HM, McGrother CW; Leicestershire MRC Incontinence Study Group
The natural history of overactive bladder and stress urinary incontinence in older women in the community: a 3-year prospective cohort study. Neurourol Urodyn. 2006;25(7):709-16.
Keay S
Cell signaling in interstitial cystitis/painful bladder syndrome. Cell Signal. 2008 Dec;20(12):2174-9. doi: 10.1016/j.cellsig.2008.06.004. Epub 2008 Jun 19. Review.

Investigating the Role of microRNAs in the Regulation of Gene Expression and Organ Remodeling During Lower Urinary Tract Dysfunction, Including Bladder Pain Syndrome/Interstitial Cystitis (BPS), and Overactive Bladder Syndrome (OAB)

Details for clinical trial NCT01482676

Clinical trial NCT01482676 - References